Evidence map›Paper›PMID 36582231›Full record

Trial reportFrontiers in immunology2022

Impact of oral administration of single strain

Mahdi Saghari, Pim Gal, Hendrika W Grievink, Erica S Klaassen, Andrea Itano, Duncan McHale, Matthijs Moerland

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mahdi SaghariCentre for Human Drug Research (CHDR), Leiden, Netherlands.
Pim GalCentre for Human Drug Research (CHDR), Leiden, Netherlands.
Hendrika W GrievinkCentre for Human Drug Research (CHDR), Leiden, Netherlands.
Erica S KlaassenCentre for Human Drug Research (CHDR), Leiden, Netherlands.
Andrea ItanoEvelo Biosciences Inc., Cambridge, MA, United States.
Duncan McHaleEvelo Biosciences Inc., Cambridge, MA, United States.
Matthijs MoerlandCentre for Human Drug Research (CHDR), Leiden, Netherlands.
Centre for Human Drug Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: The trial was registered on Netherlands Trial Register (trial ID NL7519, https://trialsearch.who.int). Eighty-one healthy subjects (median 28, range 18-59 years) were randomized to 28 days of enteric-coated capsules at five doses (n = 13) (1.5 * 10 Results: Repeated-measures analysis of covariances revealed no significant treatment effects on the antibody responses to KLH, number of Tregs, or KLH skin rechallenge outcomes. Discussion: The EDP1066 formulations did not affect the immune response to KLH immunization in healthy individuals. However, exposure to Netherlands Trial Register: trialsearch.who.int, trial ID NL7519.

Indexed as

Gastrointestinal MicrobiomeLactococcus lactisAdministration, OralAdolescentAdultCytokinesHealthy VolunteersHemocyaninsHumansImmunityImmunizationLipopolysaccharidesMiddle AgedRNA, Ribosomal, 16SYoung AdultCytokinesHemocyaninskeyhole-limpet hemocyaninLipopolysaccharidesRNA, Ribosomal, 16Sautoimmune diseasedelayed-type hypersensitivityEDP1066gastrointestinal microbiomekeyhole limpet hemocyaninLactococcus lactis spp. cremorislate-phase skin reaction

Identifiers

PMID36582231
PMCPMC9793106
OpenAlexW4311846204

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.